Harrow Introduces Innovative HAFA Program for Patients
Harrow Launches Harrow Access for All (HAFA)
HAFA to Expand Harrow’s Innovative Market Access Model Across Ophthalmic Portfolio
Program will be available in late 2025 through the HarrowAccess.com Portal
Harrow, well-known for its commitment to innovative ophthalmic solutions, has just introduced Harrow Access for All (HAFA). This program is set to enhance affordability and access to a wide range of branded, generic, and compounded ophthalmic medications. Designed as an expansion of the successful VEVYE Access for All (VAFA) initiative, which launched prior with a positive response, HAFA will provide a user-friendly portal where patients can easily access their needed medications.
The VAFA initiative specifically focused on improving access to VEVYE (cyclosporine ophthalmic solution) 0.1%, which effectively treats dry eye symptoms. By tackling both cost and bureaucratic hurdles, it quickly became evident that a patient-centered approach improves prescription rates significantly. VEVYE prescriptions spiked by 66% in a recent quarter, showcasing the effectiveness of the initiative.
Now, the HAFA program is ready to extend this successful model to include Harrow’s diverse range of ophthalmic products, facilitating patient access throughout the entire portfolio. This initiative will officially begin in late 2025, with plans for further expansion into 2027. The unified access point aims to enhance the prescribing experience for both healthcare providers and patients, ensuring ease and predictability in obtaining treatment.
CEO Mark L. Baum elaborated on the significance of HAFA, noting, “This launch is the result of years of dedicated effort to serve eyecare professionals effectively. We aim to focus on providing top-tier care while minimizing administrative burdens associated with prescriptions.” He described HAFA as an ‘Amazon for Ophthalmology’, meant to streamline practices so that healthcare providers can devote more time to patient care rather than dealing with complex procedures.
With affordability and access as core components of innovation, HAFA is focused on reducing barriers to treatment. Baum emphasized that the initiative seeks to guarantee that all patients have the opportunity to access the medications necessary for their sight preservation, irrespective of their insurance situation or financial capacity.
Key Features of the HAFA Program
Program Highlights
- Affordable Pricing: Patients with commercial insurance may pay little to nothing, with out-of-pocket costs capped at $59 for eligible individuals, ensuring affordability is maintained across the board.
- Three-phase Implementation:
- Phase 1 (Expected Q4 2025 Launch): Targeting a majority of Harrow’s specialty products, allowing eligible patients to pay as low as $0 out-of-pocket, significantly improving affordability.
- Phase 2 (Expected First Half 2026 Launch): An expansion of the AGx offerings, further increasing patient access.
- Phase 3 (Expected 2027 Launch): Encompasses the entire Harrow portfolio, making compounded medications and affordable options accessible to all patients, ensuring comprehensive support.
- HarrowAccess.com Portal: This centralized platform simplifies the prescribing process for physicians and patients alike. By streamlining prior authorizations and reducing administrative tasks, it improves efficiency in patient care.
Harrow's commitment to ensuring patients have access to essential treatments without unnecessary barriers is echoed by Dr. Ivan Mac, M.D., who praises the ease of navigation through both VAFA and the upcoming HAFA platform.
Dr. Cory Lappin, an optometrist, also supports HAFA, acknowledging how this program directly addresses existing access challenges and promotes affordability for patients—a much-needed shift in the industry.
As medications under the HAFA initiative will be dispensed through PhilRx, patients can expect hassle-free home delivery, automatically accessing all benefits without any copay cards or additional steps required.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a pioneering provider of ophthalmic disease management solutions in North America, offering a unique collection of products addressing both the anterior and posterior segments of the eye. With a core focus on safety, efficacy, accessibility, and affordability, the goal is to enhance patient compliance and improve overall clinical outcomes. To learn more about Harrow, please visit harrow.com.
Frequently Asked Questions
What is the main purpose of the HAFA program?
The HAFA program is designed to enhance access and affordability for patients needing ophthalmic medications.
When will the HAFA program be available?
HAFA is expected to launch in late 2025, with a phased rollout extending into 2027.
How does HAFA ensure medication affordability?
HAFA offers predictable pricing, with eligible patients paying as little as $0 and a maximum out-of-pocket cost of $59.
What medications will HAFA cover?
HAFA will cover a comprehensive portfolio of Harrow’s ophthalmic products, including branded and compounded medications.
How will the HarrowAccess.com portal help patients?
The portal streamlines the prescribing process, offering an efficient and supportive experience for both patients and healthcare providers.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
